Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging.
Dingemans AC, de Langen AJ, van den Boogaart V, Marcus JT, Backes WH, Scholtens HTGM, van Tinteren H, Hoekstra OS, Pruim J, Brans B, Thunnissen FB, Smit EF, Groen HJM. Dingemans AC, et al. Among authors: de langen aj. Ann Oncol. 2011 Mar;22(3):559-566. doi: 10.1093/annonc/mdq391. Epub 2010 Aug 11. Ann Oncol. 2011. PMID: 20702788 Free article. Clinical Trial.
Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.
Kuiper JL, Hendriks LE, van der Wekken AJ, de Langen AJ, Bahce I, Thunnissen E, Heideman DA, Berk Y, Buijs EJ, Speel EJ, Krouwels FH, Smit HJ, Groen HJ, Dingemans AM, Smit EF. Kuiper JL, et al. Among authors: de langen aj. Lung Cancer. 2015 Sep;89(3):255-61. doi: 10.1016/j.lungcan.2015.05.023. Epub 2015 Jun 6. Lung Cancer. 2015. PMID: 26117231
Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer.
van der Wekken AJ, Pelgrim R, 't Hart N, Werner N, Mastik MF, Hendriks L, van der Heijden EHFM, Looijen-Salamon M, de Langen AJ, Staal-van den Brekel J, Riemersma S, van den Borne BE, Speel EJM, Dingemans AC, Hiltermann TJN, van den Berg A, Timens W, Schuuring E, Groen HJM. van der Wekken AJ, et al. Among authors: de langen aj. Clin Cancer Res. 2017 Aug 1;23(15):4251-4258. doi: 10.1158/1078-0432.CCR-16-1631. Epub 2017 Feb 9. Clin Cancer Res. 2017. PMID: 28183714
PD-L1 IHC in NSCLC with a global and methodological perspective.
Thunnissen E, de Langen AJ, Smit EF. Thunnissen E, et al. Among authors: de langen aj. Lung Cancer. 2017 Nov;113:102-105. doi: 10.1016/j.lungcan.2017.09.010. Epub 2017 Sep 18. Lung Cancer. 2017. PMID: 29110835 Free article. Review.
Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.
van Veggel B, de Langen AJ, Hashemi S, Monkhorst K, Rosenberg EH, Heideman DAM, Radonic T, Smit EF. van Veggel B, et al. Among authors: de langen aj. Lung Cancer. 2018 Oct;124:130-134. doi: 10.1016/j.lungcan.2018.07.030. Epub 2018 Jul 30. Lung Cancer. 2018. PMID: 30268451 Free article.
Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer.
Niemeijer AN, Leung D, Huisman MC, Bahce I, Hoekstra OS, van Dongen GAMS, Boellaard R, Du S, Hayes W, Smith R, Windhorst AD, Hendrikse NH, Poot A, Vugts DJ, Thunnissen E, Morin P, Lipovsek D, Donnelly DJ, Bonacorsi SJ, Velasquez LM, de Gruijl TD, Smit EF, de Langen AJ. Niemeijer AN, et al. Among authors: de langen aj, de gruijl td. Nat Commun. 2018 Nov 7;9(1):4664. doi: 10.1038/s41467-018-07131-y. Nat Commun. 2018. PMID: 30405135 Free PMC article. Clinical Trial.
103 results